+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Conjugate Vaccine Market Research Report by Type, by End User, by Pathogen Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4896495
  • Report
  • July 2021
  • Region: Global
  • 192 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Conjugate Vaccine Market will Grow to USD 53.89 Billion by 2026, at a CAGR of 10.62%

FEATURED COMPANIES

  • Bharat Biotech
  • Biological E. Ltd
  • CSL Limited
  • GlaxoSmithKline, plc.
  • Merck and Company
  • Novartis AG
  • MORE
The Global Conjugate Vaccine Market size was estimated at USD 29.40 Billion in 2020 and expected to reach USD 32.43 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 10.62% to reach USD 53.89 Billion by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Conjugate Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the Conjugate Vaccine Market was examined across Monovalent and Multivalent.
  • Based on Indication, the Conjugate Vaccine Market was examined across Diphtheria and Pertussis, Influenza, Meningococcal, and Pneumococcal.
  • Based on End User, the Conjugate Vaccine Market was examined across Adults Conjugate Vaccine and Pediatrics Conjugate Vaccine.
  • Based on Pathogen Type, the Conjugate Vaccine Market was examined across Bacterial Conjugate Vaccine, Combination Conjugate Vaccine, and Viral Conjugate Vaccine.
  • Based on Geography, the Conjugate Vaccine Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Conjugate Vaccine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Conjugate Vaccine Market, including Bharat Biotech, Biological E. Ltd, CSL Limited, GlaxoSmithKline, plc., Merck and Company, Novartis AG, Nuron Biotech Inc., Pfizer, Inc., Sanofi Pasteur, and Serum Institute of India.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Conjugate Vaccine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Conjugate Vaccine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Conjugate Vaccine Market?
4. What is the competitive strategic window for opportunities in the Global Conjugate Vaccine Market?
5. What are the technology trends and regulatory frameworks in the Global Conjugate Vaccine Market?
6. What is the market share of the leading vendors in the Global Conjugate Vaccine Market?
7. What modes and strategic moves are considered suitable for entering the Global Conjugate Vaccine Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bharat Biotech
  • Biological E. Ltd
  • CSL Limited
  • GlaxoSmithKline, plc.
  • Merck and Company
  • Novartis AG
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Type Outlook
3.4. Indication Outlook
3.5. End User Outlook
3.6. Pathogen Type Outlook
3.7. Geography Outlook
3.8. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of infectious diseases
5.1.1.2. Rising adoption of cancer therapeutic vaccines
5.1.1.3. Rising number programs to promote vaccination by WHO
5.1.2. Restraints
5.1.2.1. Low accessibility to vaccines in remote areas
5.1.3. Opportunities
5.1.3.1. Government initiatives for infectious diseases
5.1.3.2. Advancement in technology of emergin pathogens
5.1.4. Challenges
5.1.4.1. Complexity of production procedure of conjugate vaccine
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Conjugate Vaccine Market, by Type
6.1. Introduction
6.2. Monovalent
6.3. Multivalent

7. Conjugate Vaccine Market, by Indication
7.1. Introduction
7.2. Diphtheria and Pertussis
7.3. Influenza
7.4. Meningococcal
7.5. Pneumococcal

8. Conjugate Vaccine Market, by End User
8.1. Introduction
8.2. Adults Conjugate Vaccine
8.3. Pediatrics Conjugate Vaccine

9. Conjugate Vaccine Market, by Pathogen Type
9.1. Introduction
9.2. Bacterial Conjugate Vaccine
9.3. Combination Conjugate Vaccine
9.4. Viral Conjugate Vaccine

10. Americas Conjugate Vaccine Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Conjugate Vaccine Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Thailand

12. Europe, Middle East & Africa Conjugate Vaccine Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Bharat Biotech
14.2. Biological E. Ltd
14.3. CSL Limited
14.4. GlaxoSmithKline, plc.
14.5. Merck and Company
14.6. Novartis AG
14.7. Nuron Biotech Inc.
14.8. Pfizer, Inc.
14.9. Sanofi Pasteur
14.10. Serum Institute of India

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2020 (USD BILLION)
FIGURE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2020 (USD BILLION)
FIGURE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2020 (USD BILLION)
FIGURE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2020 (USD BILLION)
FIGURE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
FIGURE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 8. GLOBAL CONJUGATE VACCINE MARKET: MARKET DYNAMICS
FIGURE 9. GLOBAL CONJUGATE VACCINE MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2026
FIGURE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, 2018-2026 (USD BILLION)
FIGURE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, 2018-2026 (USD BILLION)
FIGURE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 17. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
FIGURE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD BILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2026
FIGURE 20. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA AND PERTUSSIS, 2018-2026 (USD BILLION)
FIGURE 21. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA AND PERTUSSIS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 22. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, 2018-2026 (USD BILLION)
FIGURE 23. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 24. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, 2018-2026 (USD BILLION)
FIGURE 25. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 26. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, 2018-2026 (USD BILLION)
FIGURE 27. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 28. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 29. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2020 VS 2026 (USD BILLION)
FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2026
FIGURE 31. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS CONJUGATE VACCINE, 2018-2026 (USD BILLION)
FIGURE 32. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS CONJUGATE VACCINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 33. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PEDIATRICS CONJUGATE VACCINE, 2018-2026 (USD BILLION)
FIGURE 34. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PEDIATRICS CONJUGATE VACCINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 35. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2020 VS 2026 (%)
FIGURE 36. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2026
FIGURE 38. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, 2018-2026 (USD BILLION)
FIGURE 39. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 40. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, 2018-2026 (USD BILLION)
FIGURE 41. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 42. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, 2018-2026 (USD BILLION)
FIGURE 43. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 44. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 45. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 46. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 47. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 48. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 49. CANADA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 50. MEXICO CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 51. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 52. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 53. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 54. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 55. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 56. CHINA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 57. INDIA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 58. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 59. JAPAN CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 60. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 61. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 62. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 63. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 64. THAILAND CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 65. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 66. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 67. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 68. FRANCE CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 69. GERMANY CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 70. ITALY CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 71. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 72. QATAR CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 73. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 74. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 75. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 76. SPAIN CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 77. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 78. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 79. GLOBAL CONJUGATE VACCINE MARKET: FPNV POSITIONING MATRIX
FIGURE 80. GLOBAL CONJUGATE VACCINE MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 81. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CONJUGATE VACCINE MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL CONJUGATE VACCINE MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA AND PERTUSSIS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS CONJUGATE VACCINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PEDIATRICS CONJUGATE VACCINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 17. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 19. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 20. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 21. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 22. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 23. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 24. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 25. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 26. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 27. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 28. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 29. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 30. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 31. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 32. CANADA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 33. CANADA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 34. CANADA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 35. CANADA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 36. MEXICO CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 37. MEXICO CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 38. MEXICO CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 39. MEXICO CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 40. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 41. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 42. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 43. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 44. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 45. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 46. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 47. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 48. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 49. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 50. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 51. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 52. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 53. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 54. CHINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 55. CHINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 56. CHINA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 57. CHINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 58. INDIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 59. INDIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 60. INDIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 61. INDIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 62. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 63. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 64. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 65. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 66. JAPAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 67. JAPAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 68. JAPAN CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 69. JAPAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 70. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 71. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 72. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 73. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 74. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 75. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 76. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 77. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 78. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 79. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 80. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 81. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 82. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 83. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 84. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 85. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 86. THAILAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 87. THAILAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 88. THAILAND CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 89. THAILAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 95. FRANCE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 96. FRANCE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 97. FRANCE CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 98. FRANCE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 99. GERMANY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 100. GERMANY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 101. GERMANY CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 102. GERMANY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 103. ITALY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 104. ITALY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 105. ITALY CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 106. ITALY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 107. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 108. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 109. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 110. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 111. QATAR CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 112. QATAR CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 113. QATAR CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 114. QATAR CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 115. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 116. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 117. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 118. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 119. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 120. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 121. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 122. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 123. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 124. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 125. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 126. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 127. SPAIN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 128. SPAIN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 129. SPAIN CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 130. SPAIN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 131. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 132. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 133. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 134. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 135. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 136. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 137. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 138. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 139. GLOBAL CONJUGATE VACCINE MARKET: SCORES
TABLE 140. GLOBAL CONJUGATE VACCINE MARKET: BUSINESS STRATEGY
TABLE 141. GLOBAL CONJUGATE VACCINE MARKET: PRODUCT SATISFACTION
TABLE 142. GLOBAL CONJUGATE VACCINE MARKET: RANKING
TABLE 143. GLOBAL CONJUGATE VACCINE MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 144. GLOBAL CONJUGATE VACCINE MARKET: MERGER & ACQUISITION
TABLE 145. GLOBAL CONJUGATE VACCINE MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 146. GLOBAL CONJUGATE VACCINE MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 147. GLOBAL CONJUGATE VACCINE MARKET: INVESTMENT & FUNDING
TABLE 148. GLOBAL CONJUGATE VACCINE MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 149. GLOBAL CONJUGATE VACCINE MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Bharat Biotech
  • Biological E. Ltd
  • CSL Limited
  • GlaxoSmithKline, plc.
  • Merck and Company
  • Novartis AG
  • Nuron Biotech Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur
  • Serum Institute of India
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll